Menopause and Hormone Therapy: A Short Summary Before You Decide

Menopausal hormone therapy was once seen as risky for breast cancer and heart disease, and people stopped using it worldwide after 2002. Today’s understanding is very different. Perimenopause is the phase before periods end, when hormones start to fluctuate and symptoms begin; menopause is the point with no periods for 12 months; and MHT is hormone therapy used to relieve menopausal symptoms.

What Menopause Symptoms Look Like

The transition usually begins in the late 40s, lasts about 3 to 4 years on average, and the average age at menopause is around 52. The main symptoms are hot flashes and night sweats (about 80 percent), poor sleep, mood changes, brain fog, and genitourinary symptoms (about 50 percent of postmenopausal women). Menopausal brain fog is mostly temporary and improves on its own, and it is not a sign of dementia.

Why the Fear From WHI 2002 Changed

The 2002 Women’s Health Initiative trial was stopped early because of increased risks of breast cancer and heart disease, and people stopped using MHT. But the trial population averaged around 63 years old and many were more than 10 years past menopause, whereas real MHT users typically start in their early 50s.

The timing hypothesis proposes that when hormones are started determines the result. The Cochrane review found that in women who started within 10 years of menopause, coronary heart disease risk fell by about 48 percent and all-cause mortality by about 30 percent.

⚠️ Caveat: the good results appear only in the early-start group. Hormone therapy across everyone does not protect the heart, and the early-start group still had an increased risk of venous thromboembolism.

Breast Cancer Needs the Full Picture

The 20-year WHI follow-up separates the two regimens clearly. Estrogen alone (in women who had a hysterectomy) is associated with lower breast cancer incidence (HR 0.78) and lower mortality (HR 0.60), while estrogen plus progestin is associated with higher incidence (HR 1.28). But that increased risk is a small absolute number, about 8 cases per 10,000 women per year. The relative risk that sounds frightening comes from a low baseline, and reporting relative risk without the absolute figure was the root cause of the 2002 panic.

Who Fits MHT and the Non-Hormonal Options

The NAMS 2022 and IMS 2024 guidance agree that MHT offers benefits over risks in healthy women under 60, or within 10 years of menopause, who have bothersome symptoms. Women who still have a uterus must add a progestin to lower the risk of endometrial cancer, transdermal estrogen carries a lower clot risk than oral, and MHT reduces fractures only while the drug is taken.

For those who cannot use hormones, there are evidence-backed options.

• Paroxetine and Venlafaxine SSRI and SNRI drugs that modestly reduce hot flashes
• Fezolinetant (Veozah) an NK3 antagonist, not a hormone, carrying a boxed warning for the liver, and Elinzanetant (Lynkuet), a newer drug FDA-approved in 2025
• CBT reduces distress from hot flashes but not their frequency
• Low-dose vaginal estrogen works well for vaginal symptoms and is absorbed into the body very little

Compounded bioidentical hormones sold on trend lack quality evidence and fall outside FDA regulation, unlike FDA-approved bioidenticals, and testosterone in women is proven only for sexual desire.

A Small Step You Can Take

If menopause symptoms disrupt your life, talking with a gynecologist or specialist gives a better picture than deciding alone, because MHT is an individual decision that depends on age, time since menopause, and each person’s risk. Both starting and stopping hormones should be done under a doctor’s guidance.

This summary is for understanding, not medical advice, and you should consult a doctor before starting or stopping hormones. The full version contains the complete rationale and research